ITK and B-cell chronic lymphocytic leukemia: Of note, because in CLL ibrutinib treatment diminished the immunosuppressive properties of malignant cells through BTK-dependent and BTK-independent mechanisms (probably via ITK inhibition) [212], it will be interesting to observe whether the same level of anti-tumor efficacy is maintained by specific BTK inhibition alone.